ZA978865B - Reshaped human anti-HM 1.24 antibody. - Google Patents

Reshaped human anti-HM 1.24 antibody.

Info

Publication number
ZA978865B
ZA978865B ZA9708865A ZA978865A ZA978865B ZA 978865 B ZA978865 B ZA 978865B ZA 9708865 A ZA9708865 A ZA 9708865A ZA 978865 A ZA978865 A ZA 978865A ZA 978865 B ZA978865 B ZA 978865B
Authority
ZA
South Africa
Prior art keywords
chain
antibody
human
reshaped human
region
Prior art date
Application number
ZA9708865A
Other languages
English (en)
Inventor
Koichiro Ono
Toshihiko Ohtomo
Masayuki Tsuchiya
Yasushi Yoshimura
Yasuo Koishihara
Massaki Kosaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of ZA978865B publication Critical patent/ZA978865B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA9708865A 1996-10-04 1997-10-03 Reshaped human anti-HM 1.24 antibody. ZA978865B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26475696 1996-10-04

Publications (1)

Publication Number Publication Date
ZA978865B true ZA978865B (en) 1998-04-20

Family

ID=17407753

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9708865A ZA978865B (en) 1996-10-04 1997-10-03 Reshaped human anti-HM 1.24 antibody.

Country Status (19)

Country Link
US (2) US6699974B2 (cs)
EP (1) EP0960936B1 (cs)
KR (1) KR100388256B1 (cs)
CN (2) CN1765928A (cs)
AT (1) ATE512224T1 (cs)
AU (1) AU715156B2 (cs)
BR (1) BR9712488A (cs)
CA (1) CA2267072C (cs)
CZ (1) CZ296790B6 (cs)
IL (1) IL129286A0 (cs)
NO (1) NO325178B1 (cs)
PL (1) PL187642B1 (cs)
RU (1) RU2184147C2 (cs)
SK (1) SK44399A3 (cs)
TR (1) TR199900722T2 (cs)
TW (1) TW530064B (cs)
UA (1) UA76934C2 (cs)
WO (1) WO1998014580A1 (cs)
ZA (1) ZA978865B (cs)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297219T1 (de) 1997-02-12 2005-06-15 Chugai Pharmaceutical Co Ltd Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
EP0972524A4 (en) * 1997-02-28 2001-03-28 Chugai Pharmaceutical Co Ltd LYMPHOCYTE ACTIVATION INHIBITORS
KR100362974B1 (ko) * 1997-10-14 2002-11-30 츄가이 세이야꾸 가부시키가이샤 림프구계 종양에 대한 항체의 증진제
WO1999043703A1 (fr) * 1998-02-25 1999-09-02 Chugai Seiyaku Kabushiki Kaisha Technique de dosage immunochimique de l'anticorps anti-hm1.24
CA2343054C (en) 1998-09-18 2007-10-30 Chugai Seiyaku Kabushiki Kaisha Method for detection or measurement of plasmacytoma cells
EP1176194B1 (en) * 1999-05-10 2005-07-20 Chugai Seiyaku Kabushiki Kaisha Method of cell cultivation
KR20020025990A (ko) 1999-08-23 2002-04-04 나가야마 오사무 에이치엠1.24 항원의 발현 증강제
WO2001077362A1 (fr) * 2000-04-06 2001-10-18 Chugai Seiyaku Kabushiki Kaisha Dosage immunologique d'anticorps anti hm1 . 24
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
US7592005B2 (en) * 2000-12-28 2009-09-22 Kirin Beer Kabushiki Kaisha Monoclonal antibody
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
WO2002072615A1 (fr) 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Methode de purification de proteines
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
JP4297689B2 (ja) * 2001-04-13 2009-07-15 中外製薬株式会社 抗原の発現量を定量する方法
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CN101240022B (zh) * 2001-06-22 2012-07-18 中外制药株式会社 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂
CA2450898A1 (en) * 2001-07-09 2003-01-23 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
EP1475100B1 (en) * 2002-02-14 2015-05-06 Chugai Seiyaku Kabushiki Kaisha Use of acetic acid for suppressing Fe ion induced problems in formulations of anti-HM1.24 or anti-IL6R antibodies
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
EP1513879B1 (en) * 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd METHOD FOR STABILIZING PROTEIN PREPARATION
US8420789B2 (en) 2002-09-11 2013-04-16 Chugai Seiyaku Kabushiki Kaisha Method for removing DNA contaminants from a protein-containing sample
US7235376B2 (en) * 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
WO2005012531A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
JPWO2005014651A1 (ja) * 2003-08-11 2006-11-24 中外製薬株式会社 糖鎖改変抗ｈｍ１．２４抗体
JP4794303B2 (ja) * 2003-10-10 2011-10-19 中外製薬株式会社 固形腫瘍治療剤
CN102373214B (zh) * 2003-11-05 2014-07-09 罗氏格黎卡特股份公司 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体
US20060122377A1 (en) * 2004-02-19 2006-06-08 Genentech, Inc. CDR-repaired antibodies
WO2005095459A2 (en) * 2004-03-29 2005-10-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
CA2580965C (en) * 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
AU2012216702B2 (en) * 2005-08-26 2014-12-04 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
EP1931712B1 (en) * 2005-08-26 2018-12-05 Roche Glycart AG Modified antigen binding molecules with altered cell signaling activity
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8709424B2 (en) * 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
MY182178A (en) 2011-09-01 2021-01-18 Chugai Pharmaceutical Co Ltd Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
AU2014370873B2 (en) 2013-12-27 2020-06-11 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
US20170362304A1 (en) 2014-08-20 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11583576B2 (en) 2017-06-15 2023-02-21 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用
CN113226367B (zh) 2018-04-06 2025-05-06 Atyr医药公司 包括抗nrp2抗体的组合物和方法
WO2019225568A1 (ja) 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
EP3805112A4 (en) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha Filling nozzle
EP4037711A4 (en) 2019-10-03 2024-02-14 Atyr Pharma, Inc. COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
AU2023262861A1 (en) 2022-04-26 2024-11-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical-preparation-containing syringe equipped with filter

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
TW205553B (cs) * 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
CA2195557C (en) * 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
ATE297219T1 (de) * 1997-02-12 2005-06-15 Chugai Pharmaceutical Co Ltd Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
US20020034507A1 (en) * 1997-02-28 2002-03-21 Yasuo Koishihara Inhibitor of lymphocyte activation
US7052873B2 (en) * 1997-10-03 2006-05-30 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
KR100362974B1 (ko) * 1997-10-14 2002-11-30 츄가이 세이야꾸 가부시키가이샤 림프구계 종양에 대한 항체의 증진제
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド

Also Published As

Publication number Publication date
UA76934C2 (en) 2006-10-16
KR20000048884A (ko) 2000-07-25
TW530064B (en) 2003-05-01
EP0960936B1 (en) 2011-06-08
SK44399A3 (en) 2000-05-16
TR199900722T2 (xx) 1999-12-21
NO325178B1 (no) 2008-02-11
CN1235639A (zh) 1999-11-17
BR9712488A (pt) 1999-10-19
US20030129185A1 (en) 2003-07-10
PL187642B1 (pl) 2004-08-31
AU4399297A (en) 1998-04-24
ATE512224T1 (de) 2011-06-15
RU2184147C2 (ru) 2002-06-27
CA2267072C (en) 2004-11-30
NO991591D0 (no) 1999-03-31
US6699974B2 (en) 2004-03-02
CA2267072A1 (en) 1998-04-09
EP0960936A1 (en) 1999-12-01
HK1024261A1 (en) 2000-10-05
KR100388256B1 (ko) 2003-06-19
CN1765928A (zh) 2006-05-03
AU715156B2 (en) 2000-01-20
PL332742A1 (en) 1999-10-11
CN1271205C (zh) 2006-08-23
NO991591L (no) 1999-06-01
CZ117399A3 (cs) 1999-09-15
US20030045691A1 (en) 2003-03-06
CZ296790B6 (cs) 2006-06-14
US7892543B2 (en) 2011-02-22
IL129286A0 (en) 2000-02-17
EP0960936A4 (en) 2005-01-19
WO1998014580A1 (fr) 1998-04-09

Similar Documents

Publication Publication Date Title
ZA978865B (en) Reshaped human anti-HM 1.24 antibody.
AU2936395A (en) Reconstituted human antibody against human interleukin-8
IL138801A0 (en) Humanized antibody against human tissue factor and process for the preparation thereof
EP1020522A4 (en) NATURAL HUMAN ANTIBODY
IL189629A0 (en) Compositions containing human ctla-4 antibodies
EP0536275A4 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
NL300433I1 (en) Methods and compositions for the treatment of glomerulonephritis
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
WO1994011026A3 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
GR3026519T3 (en) New method of treating depression
IL173988A0 (en) RESHAPED MONOCLONAL ANTIBODIES SPECIFIC FOR IgE
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
AU4441393A (en) Granulocyte-binding antibody fragments, their preparation and use
ITBO940254A0 (it) Metodo per il miglioramento di alcune funzionalita' del corpo umano.
RU93035807A (ru) Способ лечения юношеского эпифизиолиса